Biotech company Sotira stated on Thursday that the preliminary findings of preclinical safety and efficacy studies for its groundbreaking, patent-pending vaccine alternative, KEPTIDE Covid, has shown in on-going preclinical testing to attenuate COVID-19 infection.

The company said KEPTIDE Covid is a cutting-edge therapy that holds the promise for complete attenuation of SARS-CoV2 entry in kidney and lung cells. The mechanism of KEPTIDE Covid is based in its specific interaction with the Human ACE-2 receptor; the documented dominant mechanism responsible for SARS-CoV2 viral entry into human upper and lower respiratory epithelial tissue.

Based on a report by the company's Dr Avik Roy and Dr Carl G Gottschalk, the KEPTIDE Covid's "unique formulation demonstrates a robust absorption through nasal mucosa and extremely longer half-life in lungs when applied through intranasal route."

In addition, the preventive action of KEPTIDE Covid was assessed in Coppe laboratory, a CDC-approved lab that routinely handles Wuhan-standard SARS-CoV2 virus. The report suggest that KEPTIDE Covid is 15-fold stronger in preventing Wuhan SARS-CoV2 entry in primate kidney cells compared to vehicle treated group, disclosed the company.

Concurrently, the blinded, independent experiments completed at Northwestern's KECK School of Medicine's High Throughput Screening laboratory using the gold-standard cell-free biolayer interferometry (BLItz) and fluorescence polarization (FP) assays were adopted to evaluate the affinity of KEPTIDE Covid with ACE-2 receptor, concluded the company.